F-star Therapeutics, Inc (FSTX)

Etorro trading 970x250
F-star Therapeutics, Inc (FSTX) Logo

About F-star Therapeutics, Inc

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom. Address: Eddeva B920, Cambridge, United Kingdom, CB22 3AT

F-star Therapeutics, Inc News and around…

Latest news about F-star Therapeutics, Inc (FSTX) common stock and company :

F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen
20 Oct, 2021 FinancialContent

F-star Therapeutics Ltd(NASDAQ: FSTX) hasentered into a license and collaboration agreementwithJanssen ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Oct, 2021 FinancialContent

Gainers F-star Therapeutics (NASDAQ:FSTX) shares increased by 18.74% to $7.6 during Wednesday's pre-market session. ...

F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
20 Oct, 2021 Yahoo! Finance

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitate

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
19 Oct, 2021 FinancialContent

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

12 Health Care Stocks Moving In Friday's After-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares moved upwards by 8.27% to $5.76 during Friday's after-market session. This ...

F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
16 Sep, 2021 FinancialContent

Preclinical Data Indicates a Broad Therapeutic Window for F-star’s First-in-Class Tetravalent Dual T cell Agonist

Look Under The Hood: VTI Has 10% Upside
13 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $252.89 per unit.

F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's After-Market Session
31 Aug, 2021 FinancialContent

Gainers Sonnet BioTherapeutics (NASDAQ:SONN) stock moved upwards by 20.91% to $0.68 during Monday's after-market session. Today's ...

10 Biggest Price Target Changes For Tuesday
17 Aug, 2021 FinancialContent

Citigroup cut the price target on Wix.com Ltd. (NYSE: WIX) from $320 to $250. Wix.com shares fell 1.6% to close at $202.16 on ...

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients
12 Aug, 2021 FinancialContent

F-star Therapeutics Inc(NASDAQ: FSTX) hasexpanded its clinical development strategyfor FS118 into checkpoint ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
12 Aug, 2021 FinancialContent

Company to Host Conference Call Today at 9 a.m. EDT

66 Biggest Movers From Yesterday
12 Aug, 2021 FinancialContent

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last ...

F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
10 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Sum Up The Parts: VTI Could Be Worth $250
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $249.83 per unit.

F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
04 Aug, 2021 FinancialContent
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
02 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

RSI Alert: F-star Therapeutics (FSTX) Now Oversold
27 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
26 Jul, 2021 FinancialContent

Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with Atezolizumab

Top Stocks To Watch This Week? 4 Biotech Stocks To Know
16 Jul, 2021 FinancialContent
F-star Therapeutics to Present at Upcoming Investor Conferences
09 Jul, 2021 FinancialContent

Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference

Why F-Star Therapeutics Shares Are Trading Higher Today
08 Jul, 2021 FinancialContent

F-Star Therapeutics (NASDAQ: FSTX) shares are trading higher after the company entered into an exclusive licensing agreement with ...

12 Health Care Stocks Moving In Thursday's Intraday Session
08 Jul, 2021 FinancialContent

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock moved upwards by 78.94% to $3.06 during Thursday's regular ...

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
08 Jul, 2021 FinancialContent

Upgrades For FB Financial Corp (NYSE:FBK), DA Davidson upgraded the previous rating of Neutral to Buy. In the first ...

F-star Therapeutics Stock Jumps On Licensing Pact For STING Inhibitors With AstraZeneca
08 Jul, 2021 FinancialContent

F-star Therapeutics Inc(NASDAQ: FSTX)has entered into an exclusive licensing agreementwithAstraZeneca ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
08 Jul, 2021 FinancialContent

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock moved upwards by 43.27% to $2.45 during Thursday's pre-market ...

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
08 Jul, 2021 FinancialContent

F-star Therapeutics, Inc (FSTX) is a NASDAQ Common Stock listed in , ,

970x250